Saturday, September 23, 2023
Saturday, September 23, 2023

Philips to Spotlight Integrated, Data-driven Cardiology Solutions at ESC 2022

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest integrated cardiology solutions at the European Society of Cardiology (ESC) Congress (August 26-29, Barcelona, Spain). The company’s newest innovations in cardiology help provide enhanced clinical insights, strengthen clinical confidence, drive efficiency in critical care and improve cardiac care experiences from diagnosis and treatment to home care.

The demands on cardiology departments have never been higher, driving clinicians to balance the delivery of high-quality care for a growing volume of complex patients with pressures to improve departmental efficiency. The Future Health Index 2022 global report commissioned by Philips shows cardiology leaders not only see technology infrastructure improvements as key to managing and monitoring patients over extended periods of time in out-of-hospital settings, but also key to better diagnosing and treating the rising demand of new patients.

Dr. Alexandra Goncalves, Chief Medical Officer, Precision Diagnosis at Philips:

“With our innovation in cardiology, Philips is uniquely positioned to deliver definitive diagnostics and enable personalized patient management to help improve cardiac care with greater efficiency, enhanced clinical insights and better experiences for patients and Staff”

“As health systems navigate increased demand for cardiology services and complexity of patients, they face an ongoing challenge to provide quality patient care while adjusting to an increased focus on outcomes, efficiency, and costs,” said Dr. Alexandra Goncalves, Chief Medical Officer, Precision Diagnosis at Philips. “With our innovation in cardiology, Philips is uniquely positioned to deliver definitive diagnostics and enable personalized patient management to help improve cardiac care with greater efficiency, enhanced clinical insights and better experiences for patients and staff.”
Powerful ecosystem for cardiovascular care

Philips software-defined systems deliver data-driven insights, supported by AI, to provide the right care at the right time to help better manage even the most complex cardiology cases. Smart integrated end-to-end technology streamlines communication between devices and systems to help identify and address clinical as well as operational improvements, strengthen clinical confidence, build workflow efficiency, optimize resources and help lower the cost of care. Visitors to the Philips booth at ESC will see how the company is transforming cardiac care delivery into a connected future by integrating imaging, devices, software, informatics and services including:

Precision diagnosis for cardiology – Clinically smart diagnostic solutions, streamlined workflows and actionable insights for data-driven cardiac care identify clear pathways for the most complex patient journeys. Advanced visualization solutions include Philips vendor-neutral, multi-modality image and information management workspace – IntelliSpace Cardiovascular – and its new echocardiography viewing, analysis and reporting workspace (Ultrasound Workspace), a scalable solution making its debut in the European market at ESC, that when combined with Philips Ultrasound System – EPIQ CVx -, leverages AI across a wide range of applications to provide advanced quantification and standardization with consistent on and off-cart applications. Together, these echocardiology workflow solutions help improve diagnostic confidence, enhance outcomes and operational effectiveness. Philips has also expanded access to hemodynamics at point of care for real-time blood flow assessment on its Lumify Handheld Ultrasound. In addition, Philips will spotlight its award-winning Spectral CT 7500 for exceptional cardiac imaging for a full cardiac assessment to help improve cardiac treatment pathways, and its cardiac MR portfolio of solutions including the helium-free MR 5300, Smart Workflow and AI-powered SmartSpeed, also debuting in Europe at ESC.

Minimally-invasive treatment – Philips solutions for image-guided minimally invasive therapy help physicians to decide, guide, treat and review the right care for every cardiac patient in real time. Built on Philips Image-Guided Therapy System – Azurion – the company’s next generation image-guided therapy platform, these solutions uniquely integrate best in class imaging systems and software, with specialized diagnostic and therapeutic devices to support exceptional treatment for the most complex procedures. At ESC, Philips will demonstrate how its innovative EchoNavigator software enables users of its EPIQ CVxi interventional cardiology ultrasound system to automatically fuse real-time 3D TEE (transesophageal echocardiography) with cardiac fluoroscopy X-ray imaging to monitor and assist catheter-based cardiac operations. Also featured is Coronary Suite, a fully integrated system for confident decision-making to help improve cardiac cath lab performance during percutaneous coronary intervention (PCI) procedures, and hemodynamic workflow for continuous monitoring, seamless data flow and continuity for cath lab patients.

Ambulatory monitoring & diagnostics – Philips’ portfolio of remote cardiac care solutions includes near real-time patient monitoring, telehealth, emergency and therapeutic care, and cardiac ambulatory diagnostics and monitoring solutions to provide confident care across post-acute settings for chronic disease and readmission management. Solutions, which help to enable smooth transitions from the hospital to the home, include the Philips Extended Holter – ePatch for up to 14 days of continuous, high-quality ECG recording for reliable diagnosis [1], with robust data analysis provided by cloud-based, AI-enabled Philips Cardiologs software. A recent Cardiologs study demonstrated how AI may soon predict occurrence of atrial fibrillation. Also featured at ESC is Philips Questionnaire Manager, a cloud-based SaaS solution to better manage patient reported outcomes, and Philips Care Engagement Manager, helping empower clinicians to provide the right care at the right time, in the right place, while also engaging cardiac patients to take a more active role in their at-home recovery.

Philips’ hosted cardiac ultrasound symposium session at ESC 2022

As cardiology leaders look ahead to what’s next in diagnosing and treating heart failure, Philips will host a Cardiac Ultrasound Satellite Symposium session at ESC – Echo in heart failure, what can we do better now? – Friday, August 26 at 3:30pm CET, and streamed live for those who are not attending ESC in person. The session will feature international thought leaders across the Netherlands, Italy and Spain who will share their insights on horizons in structural heart disease, the reality of using 3D for routine heart failure patients, and clinical experience with the fusion revolution. Visit Philips at ESC for more information.

Visit Philips Cardiology to learn how the company’s integrated systems, devices, informatics, software and services help deliver quick, confident diagnosis and effective treatment to improve outcomes for cardiovascular disease patients. Join Philips at ESC (Hall 3, Booth #K155) to hear how its data-driven, AI-powered smart systems and solutions help strengthen clinical confidence, streamline cardiac imaging workflows and improve the cardiac care experience for patients and staff.

Reference

[1] Patient will need to replace patch on day 5 of wear, or sooner as required.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy